Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioequivalence studies based on rate of exposure, not Cmax, under FDA consideration.

This article was originally published in The Tan Sheet

Executive Summary

RATE OF EXPOSURE MEASUREMENTS COULD REPLACE Cmax BIOEQUIVALENCE studies, FDA Division of Pharmaceutical Evaluation II Director Mei-Ling Chen, PhD, told FDA's Advisory Committee for Pharmaceutical Science June 23. "Instead of rate and extent of absorption" for determining bioequivalence, "you may characterize the drug's profile in terms of rate of exposure, which may be composed of three measures: total exposure, peak exposure and early exposure," Chen said.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088606

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel